Invenomic Capital Management LP Has $1.94 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Invenomic Capital Management LP boosted its stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 16.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 871,525 shares of the company’s stock after acquiring an additional 125,110 shares during the period. Invenomic Capital Management LP owned 0.34% of Lyell Immunopharma worth $1,944,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LYEL. WuXi AppTec Co. Ltd. acquired a new position in Lyell Immunopharma in the fourth quarter valued at about $15,871,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Lyell Immunopharma by 352.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company’s stock worth $57,000 after acquiring an additional 22,701 shares in the last quarter. SG Americas Securities LLC increased its stake in Lyell Immunopharma by 81.9% in the fourth quarter. SG Americas Securities LLC now owns 99,221 shares of the company’s stock valued at $192,000 after acquiring an additional 44,686 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Lyell Immunopharma during the first quarter valued at approximately $191,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Lyell Immunopharma during the fourth quarter valued at approximately $31,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Lyell Immunopharma in a research note on Thursday, June 27th. Bank of America dropped their target price on shares of Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, June 27th.

Lyell Immunopharma Trading Up 0.3 %

Lyell Immunopharma stock traded up $0.01 during midday trading on Wednesday, reaching $1.59. The stock had a trading volume of 230,987 shares, compared to its average volume of 974,748. The company has a fifty day moving average price of $2.03 and a two-hundred day moving average price of $2.17. Lyell Immunopharma, Inc. has a 12 month low of $1.18 and a 12 month high of $3.26. The company has a market capitalization of $404.08 million, a P/E ratio of -1.77 and a beta of -0.52.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Monday, May 6th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. On average, equities research analysts predict that Lyell Immunopharma, Inc. will post -0.85 earnings per share for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.